Newsroom
Strive to Deliver Breakthroughs
Cambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreHBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...
View morePorustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safet...
View morePorustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR we...
View moreCAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – March 6, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreCAMBRIDGE, Mass., February 14, 2023 Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Onc...
View moreHBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...
View more